Abstract |
The aberrant overexpression of Wilms tumor 1 (WT1) in myeloid leukemia plays an important role in blast cell survival and resistance to chemotherapy. High expression of WT1 is also associated with relapse and shortened disease-free survival in patients. However, the mechanisms by which WT1 expression is regulated in leukemia remain unclear. Here, we report that heat shock protein 90 (Hsp90), which plays a critical role in the folding and maturation of several oncogenic proteins, associates with WT1 protein and stabilizes its expression. Pharmacologic inhibition of Hsp90 resulted in ubiquitination and subsequent proteasome-dependant degradation of WT1. RNAi-mediated silencing of WT1 reduced the survival of leukemia cells and increased the sensitivity of these cells to chemotherapy and Hsp90 inhibition. Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2. Collectively, our studies identify WT1 as a novel Hsp90 client and support the crucial role for the WT1-Hsp90 interaction in maintaining leukemia cell survival. These findings have significant implications for developing effective therapies for myeloid leukemias and offer a strategy to inhibit the oncogenic functions of WT1 by clinically available Hsp90 inhibitors.
|
Authors | Hima Bansal, Sanjay Bansal, Manjeet Rao, Kevin P Foley, Jim Sang, David A Proia, Ronald K Blackman, Weiwen Ying, James Barsoum, Maria R Baer, Kevin Kelly, Ronan Swords, Gail E Tomlinson, Minoo Battiwalla, Francis J Giles, Kelvin P Lee, Swaminathan Padmanabhan |
Journal | Blood
(Blood)
Vol. 116
Issue 22
Pg. 4591-9
(Nov 25 2010)
ISSN: 1528-0020 [Electronic] United States |
PMID | 20651072
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Benzoquinones
- HSP90 Heat-Shock Proteins
- Lactams, Macrocyclic
- STA 9090
- Triazoles
- WT1 Proteins
- tanespimycin
- Etoposide
- Proteasome Endopeptidase Complex
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(pharmacology)
- Apoptosis
(drug effects)
- Benzoquinones
(pharmacology, therapeutic use)
- Cell Line, Tumor
- Etoposide
(pharmacology)
- Female
- Gene Expression Regulation, Leukemic
- Gene Silencing
- HSP90 Heat-Shock Proteins
(antagonists & inhibitors, chemistry, metabolism)
- Humans
- Lactams, Macrocyclic
(pharmacology, therapeutic use)
- Leukemia, Myeloid
(drug therapy, genetics, metabolism)
- Mice
- Mice, SCID
- Proteasome Endopeptidase Complex
(metabolism)
- Protein Interaction Domains and Motifs
- Protein Structure, Tertiary
- Triazoles
(therapeutic use)
- WT1 Proteins
(chemistry, genetics, metabolism)
|